PROMISE

PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) brings together translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies from 22 world-class organizations to make a breakthrough in RSV (Respiratory Syncytial Virus) research. Specifically, this initiative, funded by the Innovative Medicines Initiative (IMI), focuses on advancing scientific understanding of RSV to inform public health strategies and drive the development and introduction of new immunization and therapeutic tools in Europe. Since the development of preventive measures such as a vaccine and monoclonal anticoagulants is well advanced, PROMISE aims to prepare the implementation of these treatments and prophylactic interventions.